May 20th 2024
Jose Lutzky, MD, discussed the promise of tumor infiltrating lymphocyte therapy for difficult-to-treat advanced melanoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
mRNA-4157 Plus Pembrolizumab Continues to Improve RFS in High-Risk Melanoma
December 18th 2023Findings from 3-year follow-up of KEYNOTE-942/mRNA-4157-P201 show that the cancer vaccine mRNA-4157 plus pembrolizumab reduced the risk of recurrence or death in patients with stage III/IV melanoma following resection.
Read More
Managing Expectations of Treatment for Infiltrative Basal Cell Carcinoma
November 10th 2023In an event comoderated by Michael K. Wong, MD, PhD, FRCPC, and Anokhi Jambusaria, MD, MSCE, the 2 key opinions leaders discussed the hypothetical patient case of an 88-year-old man with a nonhealing ulcer on the lateral aspect of his nose who received a diagnosis of infiltrative basal cell carcinoma.
Read More
Adjuvant Cemiplimab Shows Survival Benefit For Responders in CSCC
October 21st 2023One-year follow-up of the phase 2 study assessing the use of neoadjuvant and adjuvant cemiplimab in patients with cutaneous squamous cell carcinoma shows a promising survival benefit that has led to a wider phase 3 study.
Read More
Addressing Skin Cancer: From Screening to Treatment
May 20th 2023In an interview with Targeted Oncology, Meredith McKean, MD, MPH of Sarah Cannon Research Institute reviewed the recent changes to the U.S. Preventive Services Task Force skin cancer screening guidelines, and discussed advances in the skin cancer treatment paradigm for those who could not prevent the disease.
Read More
Roundtable Discussion: Savvides Analyzes Role of Hedgehog Inhibitors and Immunotherapy in BCC
November 29th 2022During a Targeted Oncology case-based roundtable event, Panayiotis S. Savvides, MD, PhD, MPH, discussed with participants their experiences using hedgehog pathway inhibitors and immunotherapy for patients with basal cell carcinoma.
Read More
Tumor Infiltrating Lymphocyte Data Signal Promise for New Options to Treat Advanced Melanoma
November 16th 2022In an interview with Targeted Oncology, Ryan J. Sullivan, MD, discussed the history of tumor infiltrating lymphocyte therapy, how new data may lead to approved agents in the future, and other ways tumor infiltrating lymphocytes may be used in advanced melanoma.
Read More
Hamid Reviews Options for Patients With Basal Cell Carcinoma and Cutaneous Squamous Cell Carcinoma
November 10th 2022During a Targeted Oncology case-based roundtable event, Omid Hamid, MD, discussed the data supporting the use of hedgehog pathway inhibitors and immunotherapies for skin cancers.
Read More
Bexmarilimab Derives Overall Survival Benefit in PD-1 Blockade Refractory Melanoma
October 19th 2022Results from the melanoma cohort of the phase 1/2 MATINS show the potential of bexmarilimab monotherapy and combined with other immunotherapies across solid tumors and hematologic malignancies.
Read More
Sequential Immunotherapy and Targeted Therapy Shows OS Benefit in BRAF+ Melanoma
October 12th 2022Three different sequencing schemas for immunotherapy followed by targeted therapy in patients with BRAF V600-mutant melanoma have shown positive survival outcomes and safety consistent with results from prior studies.
Read More
IO Before BRAK/MEK Inhibition Is the Ideal Treatment Sequence for BRAF-Mutant Melanoma
October 11th 2022Data from the DREAMseq trial have answered a lingering question of how to sequence therapy for patients with advanced BRAF-mutant melanoma. This research supports immunotherapy in the first-line setting, followed by BRAK/MEK inhibitors.
Read More
Atezolizumab Triplet Induces Intracranial Responses in BRAF V600-Mutated Metastatic Melanoma
September 5th 2022In patients with BRAF V600-mutated melanoma and central nervous system metastases, treatment with atezolizumab to vemurafenib plus cobimetinib achieved a good intracranial overall response rate. Responses were all achieved with the combination in patients with BRAF wild-type tumors.
Read More
Detecting and Addressing Hard-to-Find Skin Cancers
July 14th 2022Niraj H. Mehta, MD, reviews the areas of the body where skin cancer can be hard to detect, what the skin cancer will look like on those parts of the body, risk factors for those receiving treatment, and follow-up for patients to catch recurrences.
Read More
Recommended Phase 2 Dose of Tebentafusp Shows Promise in Metastatic Uveal Melanoma
June 17th 2022A manageable side-effect profile, signal of efficacy, and 36% increase in the recommended phase 2 dose (RP2D) was seen with a step-up dosing regimen of tebentafusp in patients with metastatic uveal melanoma.
Read More